AstraZeneca's Imfinzi/Tremelimumab Combo Conquers HIMALAYA

Improves Overall Survival In Liver Cancer Patients

 
• By Kevin Grogan

After the combination's success in the non-small cell lung cancer POSEIDON study, AstraZeneca's Imfinzi and tremelimumab could now be on the way to approval as a first-line treatment for hepatocellular carcinoma.

himalaya
Astrazeneca scales the heights in HCC trial • Source: Alamy

More from Alimentary/Metabolic

More from Therapy Areas